Search Results for "How Strong Is 7 5 Meloxicam"

05:16 EDT 24th April 2017 | BioPortfolio

Matching Channels

Systemic lupus erythematosus

Lupus is a systemic autoimmune disease that can affect any part of the body. As with other autoimmune diseases, the immune system attacks the body’s cells and tissue resulting in inflammation ...

Zyme Communications

Zyme Communications provides PR and marketing services for the life science sector. We support companies to raise their profile, build corporate value, and generate interest from commercial leads...


A glycoengineered, fully humanized IgG1 monoclonal antibody with potential antineoplastic activity. Obinutuzumab, a third generation type II anti-CD20 antibody, selectivity binds to the extracellula...

Cytoplasmic Protein Tau

One of the main pillars of current drug discovery and development activities in the pharmaceutical industry for Alzheimer's disease is prevention of the accumulation of misfolded proteins, i.e. ...

Streptococcal streptococcus pneumoniae vaccine

Pneumococcal disease is a leading cause of serious illness in children and adults throughout the world. The disease is caused by a common bacterium, Streptococcus pneumoniae, or pneumococcus, a gram-p...

Matching News

Recro Pharma's IV meloxicam meets primary endpoint in phase 3 trial

Recro Pharma has unveiled positive results from its second of two Phase III clinical trials assessing intravenous (IV) meloxicam for the treatment of acute postoperative pain.

Recro's IV meloxicam passes second Phase III test

Recro Pharma Inc. (NASDAQ:REPH) gained $1.54 (20%) to $9.30 after it said IV meloxicam (N1539) met the primary endpoint of a second Phase III study to treat acute postoperative pain. The therapy signi...

Meloxicam: Ph III data

Meloxicam: Completed Ph III enrollment

Pending EC decision: Novem, meloxicam, Opinion date: 16-Mar-2017

Pending EC decision: Zeleris, florfenicol / meloxicam, Opinion date: 16-Mar-2017

Recro Pharma Completes Enrollment in Phase III Safety Study of IV Meloxicam

MALVERN, Pa., Feb. 27, 2017 (GLOBE NEWSWIRE) -- Recro Pharma, Inc. (Nasdaq:REPH), a revenue generating specialty pharmaceutical company focused on products for hospital and other acute care setti...

Veterinary medicine European public assessment report (EPAR): Meloxoral, meloxicam, Revision: 5, Authorised

Matching PubMed Articles

Polymeric nanocapsules as a technological alternative to reduce the toxicity caused by meloxicam in mice.

This study determined whether meloxicam in nanocapsules modifies stomach and liver damage caused by free meloxicam in mice. Male Swiss mice were treated with blank nanocapsules or meloxicam in nanocap...

Pharmacokinetics of meloxicam after intramuscular and oral administration of a single dose to American flamingos (Phoenicopertus ruber).

OBJECTIVE To determine pharmacokinetics after IM and oral administration of a single dose of meloxicam to American flamingos (Phoenicopertus ruber). ANIMALS 14 adult flamingos. PROCEDURES Flamingos we...

Determination of Meloxicam in Egg Whites and Yolks Using Reverse Phase Chromatography.

A new method of analysis has been developed and validated for the determination of meloxicam in egg whites and yolks. Following a liquid extraction for the whites and a solid phase extraction for the ...


Dry powder inhalers (DPIs) have been among the fastest developing inhaler forms in the past decades. Researches are focusing on the formulation of carrier-free powders to obtain a higher deep-lung dep...

Correction: Pharmacokinetics of meloxicam in red-eared slider turtles (Trachemys scripta elegans) after single intravenous and intramuscular injections.

Search Whole site using Google

Quick Search
Advertisement Advertisement